Mounjaro Guidance
Clear, evidence-based guidance on dosing, pen-click calculations, and safe use of tirzepatide.
What is Mounjaro?
Mounjaro (tirzepatide) is an FDA-approved medication from Eli Lilly for adults with type 2 diabetes. It is the first dual GIP and GLP-1 receptor agonist, a newer class of therapy that targets two incretin hormones.
By targeting two incretin hormones, it can improve blood sugar control and may support weight loss in some patients. Individual results vary.
- Dual GIP/GLP-1 receptor agonist
- Once-weekly subcutaneous injection
- Six dose strengths available (2.5–15 mg)
Weekly Dosing Schedule
A typical titration increases by 2.5 mg every 4 weeks to help minimize GI side effects. Your clinician may adjust timing or dose based on response and tolerability.
